Coppola, N. et al. Current knowledge, attitudes, and practice among health care providers in OSCC awareness: systematic review and meta-analysis. Int. J. Environ. Res. Public Health 18, 4506 (2021).

Article  PubMed  PubMed Central  Google Scholar 

Miranda-Filho, A. & Bray, F. Global patterns and trends in cancers of the lip, tongue and mouth. Oral Oncol. 102, 104551 (2020).

Article  PubMed  Google Scholar 

Jiang, M. & Li, B. STAT3 and its targeting inhibitors in oral squamous cell carcinoma. Cells. 11, 3131 (2022).

Article  PubMed  PubMed Central  Google Scholar 

Speight, P. M. et al. Screening for oral cancer-a perspective from the global oral cancer forum. Oral Surg. Oral Med. Oral Pathol. Oral Radiol 123, 680–687 (2017).

Article  PubMed  Google Scholar 

Dunn, G. P., Old, L. J. & Schreiber, R. D. The three Es of cancer immunoediting. Annu. Rev. Immunol 22, 329–360 (2004).

Article  PubMed  Google Scholar 

Garrido, F. & Aptsiauri, N. Cancer immune escape: MHC expression in primary tumours versus metastases. Immunology 158, 255–266 (2019).

Article  PubMed  PubMed Central  Google Scholar 

Akinleye, A. & Rasool, Z. Immune checkpoint inhibitors of PD-L1 as cancer therapeutics. J. Hematol Oncol 12, 92 (2019).

Article  PubMed  PubMed Central  Google Scholar 

Sharma, P. & Allison, J. P. The future of immune checkpoint therapy. Science. 348, 56–61 (2015).

Article  PubMed  Google Scholar 

Sanmamed, M. F. & Chen, L. A paradigm shift in cancer immunotherapy: from enhancement to normalization. Cell. 175, 313–326 (2018).

Article  PubMed  PubMed Central  Google Scholar 

Meng, W. et al. A systems biology approach identifies effective tumor-stroma common targets for oral squamous cell carcinoma. Cancer Res. 74, 2306–2315 (2014).

Article  PubMed  Google Scholar 

Liu, Y., Kao, H. I. & Bambara, R. A. Flap endonuclease 1: a central component of DNA metabolism. Annu. Rev. Biochem. 73, 589–615 (2004).

Article  PubMed  Google Scholar 

Balakrishnan, L. & Bambara, R. A. Flap endonuclease 1. Annu. Rev. Biochem. 82, 119–138 (2013).

Article  PubMed  PubMed Central  Google Scholar 

Wei, Q. et al. A bibliometric analysis of researches on flap endonuclease 1 from 2005 to 2019. BMC Cancer 21, 374 (2021).

Article  PubMed  PubMed Central  Google Scholar 

Yang, F., Hu, Z. & Guo, Z. Small-molecule inhibitors targeting FEN1 for cancer therapy. Biomolecules. 12, 1007 (2022).

Article  PubMed  PubMed Central  Google Scholar 

Zheng, L. et al. Fen1 mutations result in autoimmunity, chronic inflammation and cancers. Nat. Med. 13, 812–819 (2007).

Article  PubMed  Google Scholar 

Zhang, K. et al. Overexpression of flap endonuclease 1 correlates with enhanced proliferation and poor prognosis of non-small-cell lung cancer. Am. J. Pathol 188, 242–251 (2018).

Article  PubMed  PubMed Central  Google Scholar 

Zhang, Y. et al. Upregulation of FEN1 is associated with the tumor progression and prognosis of hepatocellular carcinoma. Dis. Markers 2020, 2514090 (2020).

Article  PubMed  PubMed Central  Google Scholar 

Xu, L. et al. Biological and clinical significance of flap endonuclease‑1 in triple‑negative breast cancer: Support of metastasis and a poor prognosis. Oncol Rep. 44, 2443–2454 (2020).

Article  PubMed  PubMed Central  Google Scholar 

Zhong, G. et al. The clinical significance of the expression of FEN1 in primary osteosarcoma. Int. J. Gen. Med. 14, 6477–6485 (2021).

Article  PubMed  PubMed Central  Google Scholar 

Mandai, M. et al. Dual faces of ifngamma in cancer progression: a role of PD-L1 induction in the determination of pro- and antitumor immunity. Clin. Cancer Res. 22, 2329–2334 (2016).

Article  PubMed  Google Scholar 

Zhang, J., Dang, F., Ren, J. & Wei, W. Biochemical Aspects of PD-L1 regulation in cancer immunotherapy. Trends Biochem. Sci. 43, 1014–1032 (2018).

Article  PubMed  PubMed Central  Google Scholar 

Xu, L. et al. Biological and clinical significance of flap endonuclease1 in triplenegative breast cancer: Support of metastasis and a poor prognosis. Oncol Rep. 44, 2443–2454 (2020).

Article  PubMed  PubMed Central  Google Scholar 

Larsen, E. et al. Early-onset lymphoma and extensive embryonic apoptosis in two domain-specific Fen1 mice mutants. Cancer Res. 68, 4571–4579 (2008).

Article  PubMed  Google Scholar 

Abdel-Fatah, T. M. et al. Genomic and protein expression analysis reveals flap endonuclease 1 (FEN1) as a key biomarker in breast and ovarian cancer. Mol. Oncol 8, 1326–1338 (2014).

Article  PubMed  PubMed Central  Google Scholar 

He, L. et al. FEN1 promotes tumor progression and confers cisplatin resistance in non-small-cell lung cancer. Mol. Oncol. 11, 1302–1303 (2017).

Article  PubMed  PubMed Central  Google Scholar 

Li, C. et al. Identification of Flap endonuclease 1 as a potential core gene in hepatocellular carcinoma by integrated bioinformatics analysis. PeerJ 7, e7619 (2019).

Article  PubMed  PubMed Central  Google Scholar 

Zhao, E., Zhou, C. & Chen, S. Flap endonuclease 1 (FEN1) as a novel diagnostic and prognostic biomarker for gastric cancer. Clin, Res. Hepatol. Gastroenterol. 45, 101455 (2021).

Article  PubMed  Google Scholar 

Lam, J. S. et al. Flap endonuclease 1 is overexpressed in prostate cancer and is associated with a high Gleason score. BJU Int. 98, 445–451 (2006).

Article  PubMed  Google Scholar 

Wang, K., Xie, C. & Chen, D. Flap endonuclease 1 is a promising candidate biomarker in gastric cancer and is involved in cell proliferation and apoptosis. Int. J. Mol. Med. 33, 1268–1274 (2014).

Article  PubMed  Google Scholar 

Xin, X. et al. Inhibition of FEN1 increases arsenic trioxide-induced ROS accumulation and cell death: novel therapeutic potential for triple negative breast cancer. Front Oncol 10, 425 (2020).

Article  PubMed  PubMed Central  Google Scholar 

Wang, Y. et al. Letrozole improves the sensitivity of breast cancer cells overexpressing aromatase to cisplatin via down-regulation of FEN1. Clin. Transl. Oncol 21, 1026–1033 (2019).

Article  PubMed  Google Scholar 

Flach, K. D. et al. Endonuclease FEN1 coregulates ERalpha activity and provides a novel drug interface in tamoxifen-resistant breast cancer. Cancer Res. 80, 1914–1926 (2020).

Article  PubMed  Google Scholar 

Hanahan, D. Hallmarks of cancer: new dimensions. Cancer Discov. 12, 31–46 (2022).

Article  PubMed  Google Scholar 

Becker, J. R. et al. Flap endonuclease overexpression drives genome instability and DNA damage hypersensitivity in a PCNA-dependent manner. Nucleic Acids Res. 46, 5634–5650 (2018).

Article  PubMed  PubMed Central  Google Scholar 

Sato, H. et al. DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells. Nat. Commun 8, 1751 (2017).

Article  PubMed  PubMed Central  Google Scholar 

Chabanon, R. M. et al. Mutational landscape and sensitivity to immune checkpoint blockers. Clin. Cancer Res. 22, 4309–4321 (2016).

Article  PubMed  Google Scholar 

Carlisle, J. W., Steuer, C. E., Owonikoko, T. K. & Saba, N. F. An update on the immune landscape in lung and head and neck cancers. CA Cancer J. Clin. 70, 505–517 (2020).

Article  PubMed  Google Scholar 

Rivas-Fuentes, S. et al. Restoration of peripheral intermediate and classical monocytes expressing HLA-DR in patients with lung adenocarcinoma after platinum-based chemotherapy. Technol. Cancer Res. Treat. 17 (2018).

Ghosh, C., Luong, G. & Sun, Y. A snapshot of the PD-1/PD-L1 pathway. J. Cancer 12, 2735–2746 (2021).

Article  PubMed  PubMed Central  Google Scholar 

Sun, C., Mezzadra, R. & Schumacher, T. N. Regulation and function of the PD-L1 checkpoint. Immunity. 48, 434–452 (2018).

Article  PubMed  PubMed Central  Google Scholar 

Cha, J. H., Chan, L. C., Li, C. W., Hsu, J. L. & Hung, M. C. Mechanisms controlling PD-L1 expression in cancer. Mol. Cell 76, 359–370 (2019).

Article  PubMed  PubMed Central